A 2026 BMJ Open cohort study found older adults with adequate vitamin D levels experienced slightly faster cognitive decline when taking high-dose supplements.
On January 22, 2026, researchers Hua, Lam, Mok and Cheung published a longitudinal cohort study in BMJ Open reporting that older adults with adequate vitamin D status who took supplements experienced a slightly faster cognitive decline over six years compared to non-users.
The prospective observational cohort drew its data from the U.S. Health and Retirement Study. The researchers followed participants over a six-year period across study waves 12 through 15. The group included 5,065 older adults with a mean age of 67.5 years. Women represented 61.6% of the participants, and 76.6% of the cohort identified as White.
Within this large group, vitamin D supplements were reported by 2,004 participants. This means that 39.6% of the cohort used these supplements during the study period. The research team applied linear mixed models to track changes over time and adjusted for multiple covariates. This rigorous statistical approach helps isolate the specific variables under investigation.
The statistical analysis revealed that vitamin D supplement users experienced a statistically significant faster decline in global cognitive function than non-users. The researchers reported a difference in the rate of change of -0.052 points per year. This finding carried a 95% confidence interval of -0.092 to -0.013 and a p-value of 0.010.
This pattern extended beyond general global scores and appeared in specific testing categories. The supplement-use group also experienced faster decline in executive function over the six years. The data showed a difference in the rate of change of -0.021 points per year for this metric. The executive function finding had a 95% confidence interval of -0.037 to -0.005 and a p-value of 0.010.
The most revealing detail from the BMJ Open publication emerged during sensitivity analyses. The association with faster cognitive decline was observed specifically among participants whose baseline vitamin D status was described as normal or adequate. In this subgroup, the reported p-value was 0.004.
The study did not find a comparable signal among participants classified as insufficient or deficient. For that specific group, the reported p-value was 0.826. The findings indicate that adding a supplement does not provide a cognitive advantage for people who already maintain healthy blood levels.
This distinction is highly relevant for nutrition and brain health decisions in older adulthood. Many people take vitamins as a general preventive measure without completing a blood test first. The authors’ practical recommendation was to maintain adequate dietary intake and use moderate sun exposure. They advised exercising caution about supplements without a clear medical indication.
Marion Nestle, professor emerita of nutrition, food studies and public health at New York University, favors short exposures of the skin to sunlight. She notes this is especially relevant during the summer. This approach aligns with the study's guidance to prioritize natural sources over routine pill consumption.
To understand the clinical picture, it helps to examine randomized evidence alongside observational studies. A separate 2026 report on the VitaMIND randomized trial tested supplementation prospectively rather than simply comparing self-reported users and non-users. This trial evaluated 620 adults with mild-to-moderate vitamin D deficiency and early cognitive decline.
The participants received either 4,000 IU of vitamin D3 daily or a placebo for 24 months. In that trial, vitamin D supplementation did not significantly improve the primary cognitive outcome. It also failed to improve secondary measures like working memory and verbal reasoning. The trial showed no benefits for executive-function testing, daily functioning, behavior or wellbeing.
The reported null results across these cognitive domains weaken the case for using this nutrient as a general-purpose memory enhancer. Correcting a mild-to-moderate deficiency should not automatically be promoted as a cognitive-enhancement strategy. However, the VitaMIND discussion explicitly distinguishes mild-to-moderate deficiency from severe deficiency. Supplementation remains highly valuable for specific clinical indications, including severe deficiency and bone health support.
The U.S. National Institutes of Health Office of Dietary Supplements states that vitamin D supplements can slightly increase bone strength when taken with calcium in older adults. It remains unclear whether they reduce falls or fractures.
While the BMJ Open data is compelling, readers must interpret observational results carefully. The finding was mild in magnitude and observational in nature, meaning it does not establish that vitamin D supplements cause cognitive decline or dementia. The article explicitly cautions that the result should not be interpreted as showing that the pill causes dementia.
In observational research, supplement users may have differed from non-users in ways that statistical adjustment could not fully remove. People who take supplements might differ in their underlying health and daily diet. They could also have different mobility levels, chronic disease burdens or pre-existing concerns about their memory. The accessible summary of the study does not establish which specific factors explain the association.
The reported effect sizes in the U.S. Health and Retirement Study cohort were very small. Statistical significance does not necessarily mean that an individual would notice a meaningful change in everyday memory, attention or independence. The study examined cognitive trajectories over six years, not a clinical diagnosis of dementia.
Evidence regarding this nutrient is not uniformly negative across every population or study design. A 2026 report described a small cross-sectional study of 54 adults with sleep problems and mild cognitive impairment. In that specific group, people reporting at least 5,000 IU of vitamin D daily had cognitive scores more than 13% higher than non-users.
The contrast between these scientific reports highlights the importance of context. The 5,000-IU finding concerned a very small, clinically vulnerable group rather than the broader older adult population. Because that result came from a cross-sectional design, it shows an association rather than proving that high doses improve cognition.
The NIH professional fact sheet lists a tolerable upper intake level ranging from 1,000 to 4,000 IU per day depending on age. This upper limit includes vitamin D from food, beverages and supplements. A reported intake of 5,000 IU per day therefore exceeds the commonly cited adult upper intake level.
Such high daily doses should not be adopted for memory and cognitive performance without medical supervision. The BMJ Open study does not show that the vitamin is biologically harmful to the brain at ordinary doses. It specifically highlights a slight association with faster decline when taken by people who already have adequate levels.
The accessible summary does not provide the numerical thresholds used to define adequate, insufficient or deficient levels. Readers should therefore avoid converting the finding into a specific blood-level rule without consulting a clinician. Vitamin D may still be prescribed for malabsorption, medication-related risks or other documented medical reasons.
The reported conclusion from the BMJ Open cohort was that the data do not support vitamin D supplementation as a way to prevent or slow cognitive decline in older adults who already have adequate status. Treat diet and moderate sun exposure as the primary strategies rather than relying on a capsule as a cognitive shortcut.
Building long-term lifestyle and brain resilience requires evaluating health choices objectively and speaking directly with a physician. If you currently take a supplement, do not stop abruptly based on a single news story. Ask your doctor whether a blood test or continued treatment is medically indicated for your specific situation.
Ultimately, the available evidence does not establish vitamin D supplementation as a reliable way to improve memory or executive function. Focus on broad, evidence-led daily habits rather than isolating a single nutrient.
Managing conflicting advice about nutrition, exercise, sleep and supplements often leads older adults to adopt unnecessary high-dose regimens for brain performance. Navigating these differing clinical findings creates unnecessary confusion, but FitBrainLab translates this complex observational research into clear guidance so you can build a supportive routine safely.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
